RxDoctor Payments DataLook up a doctor →

Nicole Cobo, MD

Neurology with Special Qualifications in Child Neurology · Long Beach, CANPI 1497954119

Payments from drug & device makers

$252,581in general payments, 2019–2025

Across 712 payments — averaging $354.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$172K
  • Jazz Pharmaceuticals Inc.$57K
  • UCB, Inc.$6K
  • UCB Biosciences Inc.$6K
  • AbbVie$1K
  • SK Life Science, Inc.$1K
  • plus $9K from 50 others
$33,660in research payments, 2019–2025

Across 5 payments — averaging $6732.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB Biosciences Inc.$34K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB SA12$172,323
Jazz Pharmaceuticals Inc.36$56,657
UCB, Inc.143$6,305
UCB Biosciences Inc.1$5,630
AbbVie(2 entities)66$1,417
SK Life Science, Inc.49$1,345
Neurelis, Inc.51$950
Corium, LLC28$602
Greenwich Biosciences, Inc.17$519
Supernus Pharmaceuticals, Inc.13$486
Sunovion Pharmaceuticals Inc.9$430
CSL Behring15$426
Lundbeck LLC13$359
Ironshore Pharmaceuticals Inc.22$353
Biogen12$316
Livanova USA, Inc.17$305
Aquestive Therapeutics, Inc.15$298
Neurocrine Biosciences, Inc.9$279
Eisai Inc.10$261
Acadia Pharmaceuticals Inc10$252
Tris Pharma Inc14$241
Teva Pharmaceuticals USA, Inc.9$223
Lilly USA, LLC9$189
Neuropace, Inc.2$179
Upsher-smith Laboratories LLC7$167
Aucta Pharmaceuticals, Inc.10$165
Takeda Pharmaceuticals U.S.A., Inc.8$164
Zogenix Inc.6$129
Catalyst Pharmaceuticals, Inc.5$126
Mallinckrodt Hospital Products Inc.9$122
Immedica Pharma US, Inc.4$120
Travere Therapeutics, Inc.27$117
Biohaven Pharmaceuticals, Inc.8$114
Sanofi4$97
Noven Therapeutics, LLC4$94
Johnson & Johnson3$85
Mallinckrodt Enterprises LLC3$82
Vertical Pharmaceuticals, LLC3$70
Collegium Pharmaceutical, Inc.3$59
Amneal Pharmaceuticals LLC2$51
Sarepta Therapeutics, Inc.2$47
Azurity Pharmaceuticals, Inc.2$46
Biohaven Pharmaceutical Holding Company Ltd.2$45
Amgen(2 entities)2$38
Impel Pharmaceuticals Inc.2$37
Biomarin Pharmaceutical Inc.2$36
Neos Therapeutics, LP2$35
ITF Therapeutics LLC1$28
Assertio Therapeutics, Inc.2$27
Pfizer1$24
Mirum Pharmaceuticals, Inc.1$24
Arbor Pharmaceuticals, Inc.1$22
Novartis1$20
ANI Pharmaceuticals, Inc.1$16
Zyla Life Sciences, Inc.1$16
Adlon Therapeutics L.p.1$14

How this compares

$252,581 in reported general payments places this provider in the 90th percentile of 216 neurology with special qualifications in child neurology providers in California.

See all neurology with special qualifications in child neurology providers in California →

Medicare billing

Part B allowed, 2024
$13,018
Medicare patients
20
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in Long Beach

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →